Co-expression of S100A14 and S100A16 is a predictive marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas
Ken Katono (Kanagawa, Japan), Ken Katono, Yuichi Sato, Shinichiro Ryuge, Ryo Nagashio, Masanori Yokoba, Masato Katagiri, Kazu Shiomi, Yukitoshi Satoh, Noriyuki Masuda
|   |
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Florent Baty (St. Gallen, Switzerland), Florent Baty, Martin Früh, Markus Jörger, Martin Brutsche
| |
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
Chai Chee Shee (Petaling Jaya, Malaysia), Chai Chee Shee, Liam Chong Kin, Pang Yong Kek, Kow Keng Siong, Poh Mau Ern, Wong Chee Kuan, Tan Jiunn Liang
|  |
Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7
Vera Hirsh (Montreal, Canada), Vera Hirsh, Keunchil Park, Eng-Huat Tan, Li Zhang, Kenneth O’Byrne, Michael Boyer, James Chih-Hsin Yang, Tony Mok, Jean Fan, Dan Massey, Luis Paz-Ares
| |
A case series of eight patients treated with alectinib including a case of interstitial lung disease
Yoshihiko Sakata (Kumamoto, Japan), Yoshihiko Sakata, Kodai Kawamura, Yuko Yasuda, Naoki Shingu, Keisuke Anan, Kazuya Ichikado
| |
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
Konstantinos Kaltsas (Alexandroupolis, Greece), Konstantinos Kaltsas, Stavros Anevlavis, Athanasia Pataka, Georgios Kouliatsis, Sofia Pozova, Demosthenes Bouros, Marios Froudarakis
| |
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
Jean-Paul Sculier (Brussels, Belgium), Jean-Paul Sculier, Jean-Jacques Lafitte, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Arnaud Scherpereel, Marianne Paesmans, Nathalie Leclercq, Thierry Berghmans
| |